Baseline characteristics and statistical power in randomized controlled trials: Selection, prognostic targeting, or covariate adjustment?

被引:53
作者
Roozenbeek, Bob [1 ,2 ]
Maas, Andrew I. R. [2 ]
Lingsma, Hester F. [1 ]
Butcher, Isabella [4 ]
Lu, Juan [3 ]
Marmarou, Anthony [3 ]
McHugh, Gillian S. [4 ]
Weir, James [4 ]
Murray, Gordon D. [4 ]
Steyerberg, Ewout W. [1 ]
机构
[1] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands
[2] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium
[3] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA
[4] Univ Edinburgh, Div Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland
基金
英国医学研究理事会;
关键词
covariate adjustment; heterogeneity; randomized controlled trials; selection criteria; statistical power; traumatic brain injury; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; SAMPLE-SIZE REQUIREMENTS; CLINICAL-TRIALS; ADMISSION CHARACTERISTICS; MULTICENTER TRIAL; IMPACT; VALIDATION; EFFICACY; DESIGN;
D O I
10.1097/CCM.0b013e3181ab85ec
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective. Heterogeneity of patients is a common problem in randomized controlled trials (RCTs) in various fields of clinical research. We aimed to investigate the potential benefits of different approaches for dealing with heterogeneity in a case study on traumatic brain injury (TBI). Design and Setting: Statistical modeling studies in three surveys and six randomized controlled trials. Patients: Individual patient data (n = 8033) from the IMPACT database. Interventions: We investigated the statistical power and efficiency of randomized controlled trials (RCTs) in relation to (1) selection according to baseline characteristics, (2) prognostic targeting (i.e., excluding those with a relatively extreme prognosis), and (3) covariate-adjusted analysis. Statistical power was expressed as the required sample size for obtaining 80% power and efficiency as the relative change in study duration, reflecting both gains in power and adverse effects on recruitment. Uniform and targeted treatment effects were simulated for 6 month unfavorable outcome. Results: For a uniform treatment effect, selection resulted in a sample size reduction of 33% in the surveys and 5% in the RCTs, but decreased recruitment by 65% and 41%, respectively. Hence, the relative study duration was prolonged (surveys: +95%; RCTs: +60%). Prognostic targeting resulted in sample size reductions of 28% and 17%, and increased relative study duration by +5% in surveys and +11% in the RCTs. Covariate adjustment reduced sample sizes by 30% and 16%, respectively, and did not affect recruitment. For a targeted treatment effect, the sample size reductions by selection (surveys: 47%; RCTs: 20%) and prognostic targeting (surveys: 49%; RCTs: 41%) were larger and adverse effects on recruitment smaller. Conclusions. The benefits of selection and prognostic targeting in terms of statistical power are reversed by adverse effects on recruitment. Covariate adjusted analysis in a broadly selected group of patients is advisable if a uniform treatment effect is assumed, since there is no decrease in recruitment. (Crit Care Med 2009; 37:2683-2690)
引用
收藏
页码:2683 / 2690
页数:8
相关论文
共 20 条
[1]   Subgroup analysis and other (mis)uses of baseline data in clinical trials [J].
Assmann, SF ;
Pocock, SJ ;
Enos, LE ;
Kasten, LE .
LANCET, 2000, 355 (9209) :1064-1069
[2]  
FOULKES AM, 1991, J NEUROSURG, V75, pS8
[3]   Adjustment for strong predictors of outcome in traumatic brain injury trials:: 25% reduction in sample size requirements in the IMPACT study [J].
Hernandez, Adrian V. ;
Steyerberg, Ewout W. ;
Butcher, Isabella ;
Mushkudiani, Nino ;
Taylor, Gillian S. ;
Murray, Gordon D. ;
Marmarou, Anthony ;
Choi, Sung C. ;
Lu, Juan ;
Habbema, J. Dik F. ;
Maas, Andrew I. R. .
JOURNAL OF NEUROTRAUMA, 2006, 23 (09) :1295-1303
[4]   Covariate adjustment in randomized controlled trials with dichotomous outcomes increases statistical power and reduces sample size requirements [J].
Hernández, AV ;
Steyerberg, EW ;
Habbema, JDF .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2004, 57 (05) :454-460
[5]   Predicting outcome after traumatic brain injury: Development and validation of a prognostic score based on admission characteristics [J].
Hukkelhoven, CWPM ;
Steyerberg, EW ;
Habbema, JDF ;
Farace, E ;
Marmarou, A ;
Murray, GD ;
Marshall, LF ;
Maas, AIR .
JOURNAL OF NEUROTRAUMA, 2005, 22 (10) :1025-1039
[6]   Prognosis and clinical trial design in traumatic brain injury: the IMPACT study [J].
Maas, Andrew I. R. ;
Marmarou, Anthony ;
Murray, Gordon D. ;
Teasdale, Sir Graham M. ;
Steyerberg, Ewout W. .
JOURNAL OF NEUROTRAUMA, 2007, 24 (02) :232-238
[7]   Evaluation of designs for clinical trials of neuroprotective agents in head injury [J].
Machado, SG ;
Murray, GD ;
Teasdale, GM .
JOURNAL OF NEUROTRAUMA, 1999, 16 (12) :1131-1138
[8]   IMPACT database of traumatic brain injury: Design and description [J].
Marmarou, Anthony ;
Lu, Juan ;
Butcher, Isabella ;
McHugh, Gillian S. ;
Mushkudiani, Nino A. ;
Murray, Gordon D. ;
Steyerberg, Ewout W. ;
Maas, Andrew I. R. .
JOURNAL OF NEUROTRAUMA, 2007, 24 (02) :239-250
[9]   A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury [J].
Marshall, LF ;
Maas, AIR ;
Marshall, SB ;
Bricolo, A ;
Fearnside, M ;
Iannotti, F ;
Klauber, MR ;
Lagarrigue, J ;
Lobato, R ;
Persson, L ;
Pickard, JD ;
Piek, J ;
Servadei, F ;
Wellis, GN ;
Morris, GF ;
Means, ED ;
Musch, B .
JOURNAL OF NEUROSURGERY, 1998, 89 (04) :519-525
[10]   Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury:: results of two Phase III clinical trials [J].
Morris, GF ;
Bullock, R ;
Marshall, SB ;
Marmarou, A ;
Maas, A ;
Marshall, LF .
JOURNAL OF NEUROSURGERY, 1999, 91 (05) :737-743